Key facts
- Notable investors include Entrepreneurs First, Backed.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Novogaia
- ·The full record, as it builds
Funding rounds
No funding rounds for Novogaia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Novogaia
Developer of drug discovery technologies designed to identify therapeutic compounds from fungal sources using machine learning. The company's platform offers molecular structure decoding from natural samples and target mapping capabilities, enabling pharmaceutical researchers to discover and develop medicines for unmet medical needs.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 6
- Website
- novogaia.bio/
- Ownership
- Privately Held (backing)
Novogaia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Novogaia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Novogaia in its N-PORT filings yet. We sweep new filings monthly.